- The Myeloma Beacon - https://myelomabeacon.org -
BI-505
By: Jessica Langholtz; Published: October 2, 2010 @ 10:55 pm | Comments Disabled
| Brand Name: | |
| Generic Name: | |
| Code Name: | BI-505 |
| Company: | BioInvent |
| FDA Clinical Phase: | 1 |
Description:
BI-505 is a fully human antibody that causes cell death. It binds to the protein ICAM-1 (CD54), which is more common in tumors than in normal tissue. BI-505 may therefore be used to kill cancerous cells that have ICAM-1, including multiple myeloma cells. The FDA approved Phase 1 clinical trials for BI-505 in 2009, and the studies began in January 2010.
Clinical Trials:
For a list of clinical trials studying BI-505 for the treatment of multiple myeloma, see ClinicalTrials.gov [1].
Official website for BI-505: http://www.bioinvent.com/products/pipeline/bi-505 [2]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2010/10/02/bi-505/
URLs in this post:
[1] ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/results?term=bi-505&recr=&rslt=&type=&cond=myeloma&intr=&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=
[2] http://www.bioinvent.com/products/pipeline/bi-505: http://www.bioinvent.com/products/pipeline/bi-505
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.